英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
irsutismo查看　irsutismo　在百度字典中的解释百度英翻中〔查看〕
irsutismo查看　irsutismo　在Google字典中的解释Google英翻中〔查看〕
irsutismo查看　irsutismo　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Clinical impact of circulating tumor DNA to track minimal residual . . .
    Circulating tumor DNA (ctDNA) has been studied as a non-invasive tool for disease monitoring in different cancer types Despite advances in colorectal cancer (CRC) management, it remains a leading cause of mortality and there is an unmet need for new biomarkers to guide therapeutic approaches and improve patient’s outcome after surgical resection of the primary tumor or its metastatic sites
  • Minimal residual disease in colorectal cancer. Tumor-informed versus . . .
    Circulating tumor DNA (ctDNA) analysis has emerged as a minimally invasive tool for detecting minimal residual disease (MRD) in colorectal cancer (CRC) patients This enables dynamic risk stratification, earlier recurrence detection and optimized post-surgical treatment Two primary methodologies have been developed for ctDNA-based MRD detection: tumor-informed strategies, which identify tumor
  • A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected . . .
    AbstractPurpose: Analysis of ctDNA may enable early identification of patients likely to relapse, presenting an opportunity for early interventions and improved outcomes Tumor-naïve plasma-only approaches for minimal residual disease (MRD) assessment accelerate turnaround time, enabling rapid treatment decisions and ongoing surveillance Experimental Design: Plasma samples were obtained
  • Circulating tumour DNA-Based molecular residual disease detection in . . .
    More and more studies have demonstrated that circulating tumour DNA (ctDNA)-MRD (minimal residual disease) analysis can detect recurrence earlier than imaging, and we hypothesized that patients with ctDNA+ are at greater risk of recurrence than patients with ctDNA- Detection of minimal residual disease (MRD) in colorectal cancer (CRC
  • Detection of circulating tumor DNA by tumor-informed whole-genome . . .
    Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the detection of minimal residual disease (MRD) and recurrence surveillance following cancer treatment [1] The perspective of ctDNA-based MRD detection and recurrence surveillance is to identify molecular recurrence as early as possible
  • The Future of ctDNA-Defined Minimal Residual Disease: Personalizing . . .
    Our understanding of the diagnostic and prognostic use of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has broadly expanded over the past few years The utilization of ctDNA to detect minimal residual disease is currently being employed across the continuum of cancer care The lead-time of ctDNA positivity to radiographic recurrence in stage I to III CRC is up to 9 months on
  • Feasibility of ctDNA in detecting minimal residual disease and - Frontiers
    Introduction: Approximately 50% of patients diagnosed with colorectal cancer develop colorectal cancer liver metastases (CRLM) Although curative intent liver resection provides 5-year survival of 40-50%, up to 70% of patients develop recurrence of CRLM Detection of minimal residual disease (MRD) is essential for timely, optimized treatment
  • Harnessing Minimal Residual Disease as a Predictor for Colorectal . . .
    Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC) The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize
  • Living Beyond Cancer: What is Minimal Residual Disease (MRD) and How to . . .
    MRD testing may identify cancer recurrence earlier than standard imaging techniques, which improves patient outcome is a screening of ctDNA in 342 patients with resected stage II or higher colorectal cancer Results showed that ctDNA-positive patients were more likely to recur tissue-free minimal residual disease (MRD) detection
  • Clinical impact of circulating tumor DNA to track minimal residual . . .
    Circulating tumor DNA (ctDNA) has been studied as a non-invasive tool for disease monitoring in different cancer types Despite advances in colorectal cancer (CRC) management, it remains a leading cause of mortality and there is an unmet need for new biomarkers to guide therapeutic approaches and improve patient’s outcome after surgical resection of the primary tumor or its metastatic sites
  • Feasibility of ctDNA in detecting minimal residual disease and . . .
    Citation: Kalil JA, Krzywon L, Petrillo SK, Tsamchoe M, Zlotnik O, Lazaris A and Metrakos P (2024) Feasibility of ctDNA in detecting minimal residual disease and predicting recurrence for colorectal cancer liver metastases Front Oncol 14:1418696 doi: 10 3389 fonc 2024 1418696 Received: 16 April 2024; Accepted: 19 September 2024;
  • Circulating Tumor DNA as a Real-Time Biomarker for Minimal Residual . . .
    The role of adjuvant chemotherapy (adj-CT) in stage II colon cancer remains controversial Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual disease (MRD) and predicting recurrence This systematic review and meta-analysis evaluated the prognostic value of ctDNA in stage II colorectal cancer (CRC), focusing on postoperative detection, post adj-CT outcomes





中文字典-英文字典  2005-2009